Sage Journals: Discover world-class research

Abstract

Background:

Peripheral artery disease (PAD) is a critical vascular condition characterized by arterial occlusions, primarily in the lower extremities, leading to significant morbidity. The aim of this study is to investigate the clinical outcomes after directional atherectomy combined with drug-coated balloon angioplasty in lower extremity arterial disease.

Methods:

The PANDA study is a prospective, single-arm trial that evaluated the effectiveness of the TurboHawk Plaque Excision System (THPRS) combined with drug-coated balloon (DCB) angioplasty in 96 patients with femoral-popliteal lesions. The study aimed to assess the patency rates and clinical outcomes over a follow-up period of at least 12 months.

Results:

The overall 1-year patency rate was 88.2%±3.7% and 2-year patency rate was 74.8%±5.5%. The overall 1-year free from target lesion revascularization (TLR) rate was 90.8%±3.3% and 2-year free from TLR rate was 82.5%±4.7%. The 1-year patency rate for calcified versus noncalcified lesions was 87.6%±5.2% versus 89.0%±5.2%, and the 2-year patency rate was 68.3%±8.2% versus 82.4%±6.6% (p=0.085). The 1-year free from TLR rate for calcified versus noncalcified lesions was 87.6%±5.2% versus 94.3%±3.9%, and the 2-year free from TLR rate was 77.9%±7.0% versus 87.3%±6.0% (p=0.249). The 1-year patency rate for long versus short lesions was 86.5%±5.1% versus 90.5%±5.2%, and the 2-year patency rate was 67.1%±7.7% versus 85.2%±7.1% (p=0.094). The 1-year free from TLR rate for long versus short lesions was 93.3%±3.8% versus 87.6%±5.8%, and the 2-year free from TLR rate was 78.0%±7.1% versus 87.6%±5.8% (p=0.434).

Conclusion:

The application of THPRS demonstrates good safety and efficacy, and may offer a viable option advantages in long and calcified lesions.

Clinical Impact

The PANDA Trial demonstrates that directional atherectomy (TurboHawk) combined with drug-coated balloon (DCB) angioplasty achieves high 1- and 2-year patency rates (88.2% and 74.8%, respectively) in femoropopliteal lesions, with low bailout stenting (3.7%) and TLR rates (17.1%). This approach may offer distinct advantages for long (>25 cm) and calcified lesions, where traditional DCB angioplasty alone faces mechanical limitations. For clinicians, this supports atherectomy as an adjunct to DCB in complex PAD, potentially reducing restenosis and stent dependency. The innovation lies in plaque debulking before DCB, optimizing drug delivery and vessel compliance. These findings advocate for broader adoption of combined atherectomy-DCB strategies in challenging lower extremity revascularizations.

Keywords

peripheral artery disease TurboHawk plaque excision system femoral-popliteal lesions calcified lesions long lesions

Get full access to this article

View all access options for this article.

References

Shamaki

Markson

Soji-Ayoade

, et al. Peripheral artery disease: a comprehensive updated review. Curr Probl Cardiol. 2022;47(11):101082.

Criqui

Matsushita

Aboyans

, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American heart association. Circulation. 2021;144(9):e171–e191. doi:10.1161/CIR.0000000000001005.

Barnes

Eid

Creager

, et al. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(8):1808–1817.

Behroozian

Beckman

JA.

Asymptomatic peripheral artery disease: silent but deadly. Prog Cardiovasc Dis. 2021;65:2–8.

Bevan

White Solaru

KT.

Evidence-based medical management of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(3):541–553.

Mandaglio-Collados

Marín

Rivera-Caravaca

JM.

Peripheral artery disease: update on etiology, pathophysiology, diagnosis and treatment. Med Clin. 2023;161(8):344–350.

Beckman

Schneider

Conte

MS.

Advances in revascularization for peripheral artery disease: revascularization in PAD. Circ Res. 2021;128(12):1885–1912.

Rastan

Krankenberg

Baumgartner

, et al. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. J Endovasc Ther. 2015;22(1):22–27.

Jia

Zhang

, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I. JACC Cardiovasc Interv. 2018;11(23):2347–2353.

10.

Pitoulias

GA.

The role of atherectomy in BTK lesions. A systematic review. J Cardiovasc Surg. 2022;63(1):20–24.

11.

Donas

Taneva

Pitoulias

, et al. Technical performance and reproducibility following rotational atherectomy of femoropopliteal artery occlusive lesions: analysis of the multicenter MORPHEAS registry. J Cardiovasc Surg. 2022;63:13–19.

12.

Usai

Lillu

Asciutto

, et al. Systematic review of atherectomy of inguinal arteries for atherosclerotic lesions. J Cardiovasc Surg. 2022;63(1):2–7.

13.

Krawisz

Raja

Secemsky

EA.

Femoral-popliteal peripheral artery disease: from symptom presentation to management and treatment controversies. Prog Cardiovasc Dis. 2021;65:15–22.

14.

Yuan

Yang

Wang

, et al. TurboHawk plaque rotation system for treatment of arteriosclerosis occlusion in lower extremities: a pilot retrospective study. Medicine. 2021;100(5):e23976.

15.

Stavroulakis

Schwindt

Torsello

, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;24(2):181–188.

16.

Rastan

McKinsey

Garcia

, et al. One-year outcomes following directional atherectomy of popliteal artery lesions: subgroup analysis of the prospective, multicenter DEFINITIVE LE trial. J Endovasc Ther. 2018;25(1):100–108.

17.

McKinsey

Zeller

Rocha-Singh

, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7(8):923–933.

18.

Rocha-Singh

Sachar

DeRubertis

, et al. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: the VIVA REALITY study. Catheter Cardiovasc Interv. 2021;98(3):549–558.

19.

Schroë

Sachar

Keirse

, et al. The RANGER II superficial femoral artery trial: 1-year results of the long lesion cohort. Vasc Med. 2022;27(5):457–465.

20.

Bertges

White

Cheng

, et al. Registry assessment of peripheral interventional devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions. J Vasc Surg. 2021;73(5):1702–1714.

21.

Golzar

Soga

Babaev

, et al. Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the eluvia drug-eluting stent. J Endovasc Ther. 2020;27(2):296–303.

22.

Zhou

Guo

Zhang

, et al. Efficacy analysis of drug-coated balloons in the treatment of ultra-long segment lesions of femoral popliteal artery. Ann Vasc Surg. 2024;99:82–88.

23.

Iida

Urasawa

Shibata

, et al. Clinical safety and efficacy of rotational atherectomy in Japanese patients with peripheral arterial disease presenting femoropopliteal lesions: the J-SUPREME and J-SUPREME II trials. J Endovasc Ther. 2022;29(2):240–247.

24.

Torsello

Stavroulakis

Brodmann

, et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther. 2020;27(5):693–705.

25.

Morosetti

Chiocchi

Argirò

, et al. Endovascular treatment of calcific lesions of the common femoral artery using atherectomy device associated with scoring balloon angioplasty in diabetic patients with high “major amputation” risk. Vascular. 2022;30(3):463–473.

26.

Tepe